KOSDAQElectrical Equipment137940

NextEye

₩1,781▲ 0.34%2026-11-18 close
Market Cap
₩17.5B
Turnover
₩7,656,798
Volume
4.3K
Shares out.
9.8M
PER
—
PBR
0.3×
EPS
-₩2,031
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Lodmire Lifts Nine-Month Profit; Quarterly Losses Persist

NextEye swung to a nine-month 2026 operating profit on the back of its Lodmire beauty platform, yet it posted operating losses in the second and third quarters of 2026.

  1. 1

    Nine-month 2026 revenue reached KRW 182.3 billion, up 175.0% from a year earlier, which the company described as a record high.

  2. 2

    The operating loss widened to KRW 35.6 billion in 2025, extending a four-year run of losses, and the operating margin fell from -10.5% in 2024 to -29.6%.

  3. 3

    Quarterly operating profit of KRW 3.56 billion in the first quarter of 2026 was followed by an operating loss of KRW 362 million in the second quarter and KRW 217 million in the third.

  4. 4

    U.S. subsidiary Lodmire Bio's nine-month 2026 operating profit of KRW 5.4 billion supported the group's turn to profit.

  5. 5

    The debt ratio rose from 44.3% in 2024 to 139.1% in 2025, and operating cash flow was -KRW 16.4 billion in 2025.

02

Business structure

The business driving NextEye's recent results is Lodmire, a global beauty platform. The company attributed the growth in nine-month 2026 results mainly to Lodmire's rapid expansion. Lodmire sells cosmetics and health functional foods on a membership basis, and press reports differ on how many countries it covers.

One report lists 11 countries and regions, including China, Hong Kong, Taiwan, Vietnam, Malaysia and Canada, while another says the number of countries entered has expanded to 20.

Its U.S. subsidiary Lodmire Bio reported nine-month 2026 revenue of KRW 174.4 billion and operating profit of KRW 5.4 billion, according to the company. That subsidiary accounts for most of the KRW 182.3 billion consolidated revenue for the same period.

Product lines include the anti-aging health supplement Iona Jin AKG, the ginseng-culture supplement Heracell One, and inositol, launched in April 2026. Membership grew from 200,000 at the end of 2025 to 410,000 at the end of the third quarter of 2026, and the company put the figure at 540,000 as of November 2026.

The second business is machine vision inspection equipment. A 2023 technical report listed LCD appearance inspection equipment, image-processing hardware and cosmetics as its main segments, and 2026 press coverage confirms the company still runs the inspection equipment business.

Although the company is classified under electrical equipment by industry code, the 2026 earnings driver is a consumer platform rather than power equipment, which makes direct revenue comparison with sector peers difficult.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩44.1B-₩18.1B−41.0%
2025Q4₩53.8B-₩17.6B−32.7%
2026Q1₩54.2B₩3.6B6.6%
2026Q2₩65.2B-₩400M−0.6%
2026Q3₩62.9B-₩200M−0.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩32.2B-₩4.7B-₩4.8B−14.6%−4.8%28.2%
2023₩17.7B-₩12.2B-₩16.5B−68.6%−19.6%32.6%
2024₩52B-₩5.5B-₩6.4B−10.5%−7.9%44.3%
2025₩120.1B-₩35.6B-₩40.1B−29.6%−93.2%139.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue fell from KRW 32.2 billion in 2022 to KRW 17.7 billion in 2023, a 44.9% decline, then rose to KRW 52 billion in 2024 (up 193.2% year on year) and KRW 120.1 billion in 2025 (up 130.7%), growing for two consecutive years from 2024 through 2025. 2025 was the largest year of the 2022 to 2025 period and 2023 the smallest.

Operating losses were KRW 4.7 billion in 2022, KRW 12.2 billion in 2023, KRW 5.48 billion in 2024 and KRW 35.6 billion in 2025, a loss in each of the four years. In 2025 revenue rose 130.7%, yet the operating loss widened to KRW 35.6 billion and the operating margin fell from -10.5% in 2024 to -29.6%.

The loss attributable to controlling shareholders grew to KRW 40.1 billion in 2025 from KRW 6.36 billion in 2024, and the net loss including non-controlling interests was KRW 41.3 billion. The debt ratio (total liabilities divided by total equity) rose from 28.2% in 2022 and 44.3% in 2024 to 139.1% in 2025.

At the end of 2025, total liabilities were KRW 55.5 billion and total equity was KRW 39.9 billion, of which the controlling shareholders' stake was KRW 43 billion. Operating cash flow was negative every year from 2022 to 2025, reaching -KRW 16.4 billion in 2025, the largest outflow of the four years.

On a quarterly basis, an operating loss of KRW 18.1 billion in the third quarter of 2025 and KRW 17.6 billion in the fourth quarter were followed by operating profit of KRW 3.56 billion in the first quarter of 2026.

The second quarter returned to an operating loss of KRW 362 million, and the third quarter posted a smaller loss of KRW 217 million.

Loss attributable to controlling shareholders was KRW 7.52 billion profit in the first quarter of 2026, then KRW 847 million in the second quarter (down 88.7% from the prior quarter) and a net loss of KRW 1.96 billion in the third quarter.

The net loss attributable to controlling shareholders over the last four quarters totals KRW 19 billion.

According to the quarterly report filed on November 16, 2026, consolidated revenue for January to September 2026 was KRW 182.3 billion and operating profit was KRW 3 billion, against an operating loss of KRW 18 billion in the same period of 2025.

05

Industry analysis

NextEye is classified under electrical equipment, but its businesses fall into two distinct groups. One is machine vision inspection equipment, including LCD appearance inspection systems and image-processing hardware. The other is a consumer platform selling cosmetics and health functional foods on a membership basis.

A 2023 technical report described the company as a domestic leader in machine vision systems. Demand for inspection equipment tracks capital spending on manufacturing lines such as displays, a cycle that differs from the order cycle in power equipment.

The company said Lodmire's monthly sales set a record high for six consecutive months from February to July 2026, with July sales above KRW 24 billion compared with KRW 20.8 billion in June.

Sales in overseas markets move with country-specific regulation and local consumer trends, and membership-based selling rules differ from country to country.

The machine vision business competes with domestic and foreign inspection equipment makers, while Lodmire is compared with other cross-border direct-selling platforms.

Against sector peers such as LS ELECTRIC and HD Hyundai Electric, the demand drivers differ, so a comparison of sector-average positioning offers limited insight.

06

Outlook

The company said it will widen its product portfolio and the countries it serves while pursuing cost efficiency, aiming to sustain revenue growth and better profitability.

Product lines are expanding with inositol, launched in April 2026, and the company plans to keep growing by broadening both product lines and regions. Membership rose from 410,000 at the end of the third quarter of 2026 to 540,000 as of November 2026, according to the company.

Whether the streak of record monthly sales, which ran from February to July 2026, continues into the second half of 2026 is the next thing to watch.

Whether fourth-quarter 2026 revenue exceeds the KRW 53.8 billion booked in the fourth quarter of 2025, and whether operating losses extend to a third consecutive quarter, are also key checkpoints.

How the gap between Lodmire Bio's KRW 5.4 billion operating profit and the group's KRW 3 billion operating profit is explained in periodic filings is another point to confirm. Machine vision order and capacity plans will be verified only through company disclosures. The most direct checkpoint is whether annual operating profit turns positive in the 2026 annual report.

07

Valuation

PER
—
PBR
0.3×
ROE
-31.9%
EPS
-₩2,031
BPS
₩5,943
Dividend per share
₩0

With no earnings-based measure available, comparisons lean more on net asset value. Because net losses attributable to controlling shareholders have accumulated over the last four quarters, the P/E ratio cannot be calculated.

The price-to-book ratio sits well below 1x, meaning the share price is low relative to net assets. Market capitalization is also below the book value of the controlling shareholders' equity. The company pays no dividend, so a dividend-based comparison does not apply.

However, with the debt ratio rising from 44.3% in 2024 to 139.1% in 2025 and the capital structure thinning, how stable book value remains is the next point to confirm. Reading the pace at which net assets shrink alongside the timing of any turn to operating profit is the most factual way to frame the comparison.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Cumulative profit turn and record revenue

The record revenue came amid sales growth driven by a larger membership base. The company also reported a cumulative operating profit of KRW 3 billion and net income of KRW 6.5 billion for the period, both swinging to profit from a year earlier. It said the nine-month revenue equaled about 1.5 times full-year 2025 revenue.

Rapid growth in members and monthly sales

Membership rose from 200,000 at the end of 2025 to 410,000 at the end of the third quarter of 2026, and the company put it at 540,000 as of November 2026. Monthly sales set a record for six straight months from February to July 2026. July sales topped KRW 24 billion, above the KRW 20.8 billion booked in June.

Portfolio expansion and cost efficiency plans

Inositol, launched in April 2026, is contributing to sales, and the company plans to widen its product lines and regions. It also said it will pursue cost efficiency alongside growth to improve profitability.

The company already posted an operating profit of KRW 3.56 billion in the first quarter of 2026, which is cited as evidence of improving earnings structure.

09

Bear factors

Quarterly losses return

The company swung from an operating profit in the first quarter of 2026 to an operating loss of KRW 362 million in the second quarter, followed by a KRW 217 million loss in the third. The 2025 operating loss of KRW 35.6 billion widened sharply from KRW 5.48 billion in 2024.

Because the first-quarter profit reversed within two quarters, the durability of quarterly profit has yet to be shown.

Financial strain and negative cash flow

The debt ratio jumped to 139.1% in 2025 from 44.3% in 2024. Total liabilities of KRW 55.5 billion at the end of 2025 exceed total equity of KRW 39.9 billion. Operating cash flow was negative every year from 2022 to 2025, and the 2025 outflow of -KRW 16.4 billion was the largest.

Earnings concentrated in one business

The nine-month profit leans heavily on Lodmire's operating income. Lodmire Bio's cumulative operating profit of KRW 5.4 billion is larger than the group's KRW 3 billion. If overseas platform sales slow, the cumulative profit trend could be disrupted, which is the main bear point.

10

Risk factors

Overseas sales regulation and country mix

Membership-based sales face different regulations and tax rules in each country. Press reports differ on the number of countries, with some citing 11 countries and regions and others 20. A change in the country mix could increase earnings volatility.

Financial leverage and cash generation

The debt ratio reached 139.1% in 2025 and operating cash flow was -KRW 16.4 billion. Total equity is smaller than the controlling shareholders' stake, so further losses could erode capital capacity quickly. How annual operating results and cash flow appear in the 2026 annual report will be important.

Quarterly earnings volatility and small-cap profile

Net income attributable to controlling shareholders fell from KRW 7.52 billion in the first quarter of 2026 to KRW 847 million in the second, then became a KRW 1.96 billion net loss in the third. Quarterly results swing widely, which makes the annual earnings trend hard to gauge. As a small-cap stock, the share price may react more strongly to swings in quarterly results.

11

What to watch next

  1. December 31, 2026 (end of Q4 2026)

    Whether Q4 2026 revenue exceeds the KRW 53.8 billion of Q4 2025, and whether an operating loss extends to a third straight quarter.

  2. December 2026

    Whether membership growth beyond 540,000 as of November 2026 and the monthly sales record run continue.

  3. Around March 31, 2027 (annual report filing deadline)

    Whether annual operating profit turns positive, whether the debt ratio (139.1% in 2025) and operating cash flow improve, and how the gap between Lodmire Bio's KRW 5.4 billion and the group's KRW 3 billion operating profit is explained.

12

Overall view

NextEye's nine-month 2026 results show a turn in both revenue and profit. Cumulative revenue of KRW 182.3 billion equals about 1.5 times full-year 2025 revenue, and cumulative operating profit of KRW 3 billion compares with an operating loss of KRW 18 billion in the same period of 2025.

On a quarterly basis, however, the second and third quarters of 2026 were operating losses in two consecutive quarters, and net income attributable to controlling shareholders turned into a loss in the third quarter.

The 2025 operating loss of KRW 35.6 billion and the 139.1% debt ratio also show a heavy financial burden. Lodmire Bio, the U.S. subsidiary, led the turn to profit, and the business is concentrated on the Lodmire platform. The price-to-book ratio sits well below 1x, while the P/E ratio cannot be calculated.

The next points to confirm are fourth-quarter 2026 results, the annual operating result and debt ratio in the 2026 annual report, and the trend in Lodmire membership and monthly sales.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. google.com
  2. kokstock.com
  3. investing.com
  4. markets.hankyung.com
  5. news.nate.com
  6. vegannews.co.kr
  7. ssl.pstatic.net
  8. ssl.pstatic.net
  9. asiae.co.kr
  10. view.asiae.co.kr
  11. news.nate.com
  12. sentv.co.kr
  13. news.nate.com
  14. supple.kr
  15. newsway.co.kr
  16. edaily.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis